BOLD — Boundless Bio, Inc. Common Stock

Boundless Bio, Inc. Common Stock (BOLD) is a biotechnology company listed on NASDAQ. It is led by Zachary Hornby, based in 10955 Alexandria Way, San Diego, CA, United States, 92121, with about 64 employees. Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA (ecDNA). The company's lead product candidate is BBI-355, an ecDNA-directed therapeutic candidate and oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. It also develops BBI-098, a picomolar biochemical inhibition of checkpoint kinase 1 demonstrating central nervous system penetrance in preclinical models. In addition, the company offers ECHO, an ecDNA harboring oncogenes diagnostic test to detect ecDNA in patient tumor specimens; and Spyglass platform, a platform used to identify druggable targets in oncogene amplified cancers. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Net income was -$13.9M. BOLD currently screens at market cap $24.6M and trailing P/E 0.1.

On the latest cached filing, BOLD: SECURITIES AND EXCHANGE COMMISSION (8-K 2026-08-28). This BOLD stock page is the analysis view: what changed in the numbers, and why it matters for Boundless Bio, Inc. Common Stock.

Use this BOLD page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the BOLD quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the BOLD SEC filings page. Lician reads the product cache first so this HTML stays unique to Boundless Bio, Inc. Common Stock even when a live quote feed is slow.